Workers and employers are drowning in their health insurance premiums. The reason for that deluge: the health care industry’s high and inscrutable prices.

Health insurers don’t set their premiums in a vacuum. The biggest factor is the care people receive. And the biggest factor driving the cost of that care, STAT has found, is not how often people are going to the hospital or doctor’s office, but the out-of-control prices charged by every part of the health care industry, which workers and businesses are often powerless to stop.

For Gerard Anderson, America’s high prices are as obvious, yet unnoticeable, as the oxygen we breathe. He has studied health care spending and policy for the past four decades, even helping design Medicare’s hospital payment system in the 1980s. He co-wrote a seminal paper in 2003, and again in 2019, that blared the culprit of America’s outlier health spending figures: “It’s the prices, stupid.” 

“Some things don’t change,” Anderson, a professor at Johns Hopkins, told STAT. 

Continue to STAT+ to read the full story…

This post was originally published here. 

Karl Deisseroth, Peter Hegemann, and Georg Nagel are the joint recipients of the 2026 Nobel Prize in Physiology or Medicine “for their discoveries concerning light-gated ion channels and optogenetics,” the Karolinska Institutet in Stockholm, Sweden announced on Monday. 

Deisseroth, 55, a professor at the Howard Hughes Medical Institute and Stanford University; Hegemann, 72, a professor at Humboldt University in Berlin; and Nagel, 73, a professor at the University of Würzburg, Germany, developed a method that uses light, combined with genetic modifications of neurons, to switch on or off individual cells in a living brain. This makes it possible to show how nerve cells shape memories, feelings and behavior in the brain, and is being studied as a treatment for disease. 

Read the rest…

This post was originally published here. 

WASHINGTON — Stem cell entrepreneur Chuck Meeker is bullish about his industry’s prospects with the Food and Drug Administration nowadays. 

“If I were a betting man, I would say before the end of the year we have a series of FDA roundtables happening,” Meeker told STAT at PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine. (The FDA declined to say whether such events were imminent.) 

That stem cells made an appearance at a conference centered on peptides isn’t a coincidence. Peptides and stem cells are two peas in the pod of regenerative medicine, which focuses on therapies that claim to trigger the body’s natural healing mechanisms. But while compounded peptides are having a bit of a moment with the FDA, commercially available, unapproved stem cell therapies have remained a black sheep for the agency. 

Meeker and others at PepMed told STAT they believe that’s about to change. The stem cell industry sees the FDA’s tentative embrace of peptides as its chance to get a foot in the door — and bring stem cells from the grey market to millions of Americans. 

Continue to STAT+ to read the full story…

This post was originally published here. 

On Monday morning, the Nobel Prize for medicine was announced. This year, I wonder: Will Claude or a future artificial intelligence agent ever win the most prestigious award for medical discovery?

Imagine a future AI agent responding to a scientist’s insightful prompt by successfully identifying a completely novel approach to curing cancer, along with a detailed and actionable plan for implementing it. Given the toll of cancer on our species, I suspect few today would consider that a bad outcome.

Read the rest…

This post was originally published here. 

The recent success of a late-stage mRNA cancer vaccine, showing the drug stopped the return of melanoma, has boosted hopes that the approach can be successfully harnessed to attack other cancers. 

The question now is which ones — and whether mRNA is up to the task. 

Merck and Moderna reported in August that adding their mRNA cancer vaccine to an existing treatment slowed the return and spread of melanoma. The field had been waiting “with bated breath” for the news on the drug, called intismeran autogene, said Karen Knudsen, the CEO of the Parker Institute for Cancer Immunotherapy, the research organization founded by tech entrepreneur Sean Parker. The results suggested that the idea of using messenger RNA to train the immune system to attack cancer cells — an approach first devised decades ago — was ripe for further drug development. 

Continue to STAT+ to read the full story…

This post was originally published here. 

In a single generation, energy drinks have conquered the beverage world.  Starting as an upscale version of the humble NoDoz pill, then sugared up for guzzling, they are now the caffeine jolt of choice for the sluggish and the sleep-deprived. In an odd commercial convergence, they have also hooked up with the burgeoning wellness movement by adding favorites like ginseng, vitamins, and amino acids to the mix, making the energy drink seem like a friendly sports drink. Presto! An $85-billion-a-year (and growing) global market is upon us.   

Which is fine. Caffeine in whatever form, be it in coffee or tea or Coca-Cola, has long been a staple of the American kitchen table.

Read the rest…

This post was originally published here. 

President Donald Trump is promising more payments to voters just ahead of the Nov. 3 midterm elections — this time, to more than 20 million seniors, giving them $90 each to help pay for Medicare premiums.

The announcement, made late Friday night by Trump on social media, comes after the president last month said about 1 million people would get rebate checks of $500 for Affordable Care Act premiums. He has also promised on the campaign trail to send every American adult $5,000 if Republicans retain control of the House and Senate in the midterm elections.

Read the rest…

This post was originally published here. 

Finding information from the National Institutes of Health about human health, disease, and biomedical research is about to look a lot different. On Monday, the NIH will unveil a new version of its website that shifts attention away from individual institutes and centers and towards eight thematic hubs focused on health, research, data, clinical studies, rare diseases, technology, cancer, and grants.

Agency officials say the redesign — which is part of an ambitious project to consolidate the NIH’s digital footprint — is intended to streamline what was a sprawling and fractured information ecosystem, requiring users to understand NIH’s organizational structure, into an intuitive experience that more closely reflects what type of information people seek out most often. 

Read the rest…

This post was originally published here. 

Some 20 years ago, Mary-Claire King was asked to hold a seminar at the Karolinska Institutet in Stockholm. 

The invite, the geneticist soon learned, was code for: You are being considered for a Nobel Prize. She traveled to Sweden, held the seminar, then spoke about her work with interested experts who she later understood to be the prize committee. 

Read the rest…

This post was originally published here. 

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Mosquitos are eating us alive into October; I just annihilated an Aedes albopictus that was supping on my shoulder. Is there a Kalshi market for wagers on when dengue will hit SoCal?

The need-to-know this morning

  • Novartis is paying $575 million upfront to license an experimental mRNA-based autoimmune therapy from the Chinese firm Abogen Biosciences, the latest case of a large pharma company looking to China to restock its pipeline.

NIH dollars are flowing, but uncertainty persists

The National Institutes of Health spent the $34 billion it was allocated by Congress for research grants in the 2026 fiscal year, but a slower and increasingly opaque funding process is now making it harder to actually do science, a STAT analysis shows.

Continue to STAT+ to read the full story…

This post was originally published here. 

BUNIA, Congo — Congo’s Ebola outbreak has killed more than 4,000 people, authorities said, as they struggle to contain what has become the fastest-growing Ebola outbreak in history.

The latest figures released by the Health Ministry on Thursday showed that 4,018 people have died among 8,300 cases recorded since the outbreak was declared in eastern Congo on May 15.

Read the rest…

This post was originally published here. 

In 2016, the American Academy of Pediatrics issued a policy statement urging doctors to offer medications for opioid use disorder to adolescent and young adult patients who needed them.  

New national data show that more young people with an opioid use disorder diagnosis did start receiving addiction medications like buprenorphine and methadone, but the increase was small. And the number of young people who stayed on medication for six months — already quite low — may have actually decreased. 

Read the rest…

This post was originally published here. 

Independence Blue Cross will pay to resolve allegations it defrauded Medicare by inflating diagnosis codes for MA beneficiaries. The payer said its settlement and others reflect “industry-wide challenges” in applying MA’s risk adjustment standards.

This post was originally published here. 

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan to tidy up around the castle, promenade extensively with the official mascots, and escort Mrs. Pharmalot to a roadside tavern. We also hope to have time for another listening party, where the rotation will likely include this, this, this, this, this and this. And what about you? The world is at your fingertips, you know, so this might be a lovely time to enjoy the great outdoors as the seasons turn. If the weather fails to cooperate, you could gather with friends and play a board game — remember those? — or put on your chef’s hat and cook a good meal. You could also plan the rest of your life, before an AI bot does it for you. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

An obesity drug from Boehringer Ingelheim and Zealand Pharma helped patients with diabetes shed as much as 13.1% of their weight, a disappointing result, Bloomberg News tells us. Boehringer has pitched the medicine as a way to help patients lose fat while preserving muscle, but without an edge, the drug becomes just one more contender in an increasingly crowded market dominated by Eli Lilly and Novo. Boehringer pushed back at the idea that the drug might only be a niche product, saying that upcoming studies in heart and liver health will more clearly show its potential.

The upcoming midterm elections are setting the stage for unusually significant changes to key Senate committees that play an important role in health care, STAT explains. Both the finance and health committees could undergo major changes, though for different reasons. Of course, if Democrats take control of the Senate, they would get to run the committees, though the GOP membership changes could still influence the panels’ directions. Specifically, five or more of the Senate Finance Committee’s 14 Republicans are set to leave. And the outlook for the Senate’s Committee on Health, Education, Labor, and Pensions, or HELP, is even more difficult to predict with the departure of chairman Bill Cassidy.

Novartis signed a licensing deal worth about $7.8 billion with Chinese biotech company Abogen to ​advance RNA-based therapy, Reuters says. Novartis will ​gain exclusive rights to Abogen’s experimental ⁠drug, ABO2203, and options to ​license other therapies based on ​Abogen’s RNA technology. It will also have the option to license additional experimental ​medicines developed using Abogen’s RNA ​platform. The drug is ⁠designed to treat autoimmune diseases by targeting B ​cells, a type of ​immune ⁠cell that causes disease in conditions like lupus and rheumatoid arthritis.

Continue to STAT+ to read the full story…

This post was originally published here. 

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Hi, it’s Sarah subbing in. I have some embarrassing memories of struggling to do even a single pull-up for the Presidential Fitness Test as a kid, so it is with great interest that I’m following the Trump administration’s efforts to revive the test for today’s unsuspecting schoolchildren. Send me your 10-minute-mile tales at sarah.todd@statnews.com.

Read the rest…

This post was originally published here. 

A STAT analysis of National Institutes of Health spending shows that in the 2026 fiscal year, which ended Wednesday, the agency continued reducing grant awards involving health disparities, race, and ethnicity but made little progress toward other Trump administration priorities, including disbursing funds more evenly across the country and expanding support for early-career scientists.

While the agency, like last year, spent its entire external grants budget of roughly $34 billion after a slow start, the manner in which it did so is sowing deep uncertainty among researchers. In a survey and interviews, they said delays in the grant review process are slowing down the pace of their work, and making it difficult for them to propose and conduct the sort of innovative, impactful science that the NIH exists to support.

Overall, the agency funded around 58,000 projects, a slight drop from the 61,000 awarded during the 2025 fiscal year and well below the roughly 63,700 grants awarded annually in the years before the second Trump administration. Though this number may increase somewhat in the coming weeks because of reporting lags in the NIH grants database, the smaller number of grants potentially resulted from the White House’s push to fully fund more multiyear grants in advance, which meant that there was less funding on hand to issue new awards. 

Continue to STAT+ to read the full story…

This post was originally published here. 

As sure as the sun rises, Crohn’s disease is most definitely not juvenile idiopathic arthritis. But government policy doesn’t seem to understand that.

I’m a pharmacist, and I started a specialty pharmacy in the small town of Sidney, Neb. My pharmacy patients drive miles and hours across the sun-drenched Nebraska prairie to see me at my pharmacy. They are often overjoyed to arrive at my counter to pick up medications like Rinvoq. No longer do they have to deal with remote mail-order pharmacies — they can come to my pharmacy anytime to speak with me and pick up their medications for things like Crohn’s disease in person. 

Read the rest…

This post was originally published here. 

Though I have treated thousands of patients since, Nov. 6, 2022 — the day of a record hot New York City Marathon — still weighs on me. Around the three-and-a-half-hour mark of the race, the finish-line medical tent filled. Inside, I was volunteering as a medical provider and an amateur runner, assigned to a row of cots in the moderate-severity zone. The unseasonably climbing temperatures were taking a visible toll on athletes of all levels.

A volunteer wheeled into my zone a middle-aged man — I’ll call him John — who had collapsed at the finish line. I asked him his name; he answered without hesitation. 

Read the rest…

This post was originally published here. 

People who have a Medicare Advantage plan — and wind up needing care and prescriptions next year — are in for a rude awakening.

Medicare Advantage insurers are raising out-of-pocket costs for enrollees, drastically cutting money for dental work and other benefits, and eliminating plans that have broad networks of hospitals and doctors, according to federal data released this week and analyzed by STAT and several investment firms. That could result in more shock for older adults, like discovering their doctor is no longer accepted by their plan, if they don’t shop carefully during Medicare’s annual enrollment period for 2027 plans, which starts Oct. 15.

Big companies like UnitedHealth Group, Humana, and others are chasing higher profits by pruning benefits, after investors grew dissatisfied with margins that were smaller than the insurers had promised. The changes in plans even come even after the industry won a payment increase and delayed reforms from the Trump administration in April.

Continue to STAT+ to read the full story…

This post was originally published here. 

Ovulation. Endometriosis. And especially: menopause. These once taboo words — among others — have become part of our daily vocabulary and conversations, a sign of greater interest in, and knowledge of, women’s health. 

Yet even as women’s health has been receiving more attention than perhaps ever before, women remain poorly represented in clinical trials, and female health poorly understood compared to male health. Much of the attention remains focused on the reproductive aspects of women’s health.

Read the rest…

This post was originally published here. 

Ten drugmakers will see 21 of their drugs move from upfront discounts to after-the-fact payments in the drug discount program at the start of next year, an expansion from the Trump administration’s first attempt at kickstarting a rebate pilot.

This post was originally published here. 

A proposed redesign of the federal government’s annual health survey would result in significant undercounting of Americans with intellectual and developmental disabilities, according to advocates for the vulnerable population.

The National Health Interview Survey has historically undercounted people with disabilities, but the changes are a “head-scratcher,” said Katy Neas, CEO of The Arc, an advocacy group. “If we don’t have the government as a trusted source of data, asking questions about real people and what their real experiences are, we’re never going to get better [health outcomes],” she said.

Read the rest…

This post was originally published here. 

On this week’s episode of “The Readout LOUD”: Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko about the impact of Americans’ growing skepticism of science. 

Your co-hosts also chat about a clinical update from UniQure on its gene therapy for Huntington’s disease, a juicy lawsuit filed by the gene-editing company Beam Therapeutics against a Chinese competitor, and a shift in the way pharma companies like Novo and Eli Lilly are talking about their GLP-1 products.

Read the rest…

This post was originally published here. 

The company will focus on automating and modernizing processes, better managing suppliers, partners and vendors and making employees more efficient, executives said during a Wednesday investor day.

This post was originally published here. 

Although artificial intelligence has quickly become integrated into our daily lives, Americans say they’re becoming increasingly concerned about their health data, making them less likely to use it for tasks like finding providers, according to a new survey.

This post was originally published here. 

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

I am newly enamored with Hans Zinsser, a Harvard bacteriologist who in 1935 wrote “Rats, Lice and History,” a rather charming “biography” of typhus. Got it for a buck at an estate sale.

Favorite line: “there is no arsphenamin for the psychic treponema” — which, in context, basically means, “pretension has no cure.”

Continue to STAT+ to read the full story…

This post was originally published here. 

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Blue Shield of California is one of 17 major health plans that has committed to adopting payment models inspired by the Medicare Innovation Center’s ACCESS Model.

The insurer’s chief medical officer Ravi Kavasery told me that it’s still figuring out details of what this will look like, including whether it will adopt CMS payment amounts and what organizations it will work with. He said Blue Shield of California, which serves 6 million members, expect to launch similar models in commercial plans in 2027. 

Continue to STAT+ to read the full story…

This post was originally published here. 

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would advise that “Every new day should be unwrapped like a precious gift.” While you tug on the ribbon, we are brewing still more cups of stimulation and invite you to join us. Remember, a prescription is not required. Our choice today is butter pecan — spiked with bourbon honey. Yummy. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …

The Trump administration published a final rule aimed at lowering Medicare prices for drugs administered in doctor offices, but it applies to only four companies and saves 96% less than initial proposal, STAT notes. The Global Benchmark for Efficient Drug Pricing, or GLOBE, is one of two mandatory pilot programs that are part of President Trump’s plan to get drugmakers to lower prices in Medicare to levels charged in other rich countries, a policy generally referred to as most-favored nation pricing. The other pilot, called GUARD, is still in the proposed stage.

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high rates of people stopping the treatment may raise questions about its tolerability, STAT writes. Lilly tested different combinations of its blockbuster GLP-1 drug Zepbound with eloralintide, a candidate that targets the amylin hormone, in people with obesity and type 2 diabetes. After 48 weeks, participants who stayed on the treatment at the highest dose of the combination therapy lost 23.3% of their weight. That is more than the weight loss seen with those taking only Zepbound and those taking only the highest dose of eloralintide — 14.8% and 11.1%, respectively.

Continue to STAT+ to read the full story…

This post was originally published here. 

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

An update on Invivyd, the small biotech company developing an injectable, low-dose monoclonal antibody to protect against Covid-19 infection like a vaccine does, but without the real or perceived limitations of vaccines. I last wrote about Invivyd in this newsletter in August 2025.

On Tuesday, Invivyd reported the results from a Phase 3 study called LIBERTY that demonstrated the superior safety and tolerability of its antibody candidate, VYD2311, compared against Comirnaty, the established mRNA-based Covid vaccine marketed by Pfizer. After six days, 57% of study participants who had VYD2311 injected into the muscle of their upper arm reported headaches, chills, fatigue or pain at the injection site — the typical side effects associated with vaccinations. In the Comirnaty arm of the study, 91% of participants reported the same side effects. The difference was statistically significant. The same study showed VYD2311 was also better tolerated at 56 days, and could be combined safely with Comirnaty.

Continue to STAT+ to read the full story…

This post was originally published here. 

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

Lauren Holder is an advocate for the Huntington’s disease community who is also living with the early stages of the progressive and fatal neurodegenerative condition. I called her Tuesday to get her reaction to UniQure’s gene therapy clinical update.

The UniQure treatment, called AMT-130, slowed the progression of Huntington’s by 44%, based on a four-year analysis of 12 treated patients. Last year, the company reported a three-year update showing a 75% slowing of disease progression. The treatment effect of AMT-130 seems to have waned from year three to four, for reasons that don’t alarm UniQure but that have raised some outside questions about the therapy’s durability.

Continue to STAT+ to read the full story…

This post was originally published here. 

SHANGHAI — The biotech executives appeared triumphant.

It was a balmy, overcast Sunday here in the glimmer-and-glass “Science City” district, and the four leaders were on stage at the ballroom level of the five-star Hilton, joking about how much faster, cheaper, and more efficient drug development was here in China than anywhere else — certainly than the United States. (And God help Europe.)

Zhui Chen, co-founder of the now $6 billion Shanghai-based biotech Abbisko, recalled running a trial on a drug licensed to the German pharma Merck KGaA. Abbisko’s trial finished in 11 months, so quickly that Merck executives asked if Abbisko could train their staff.

Continue to STAT+ to read the full story…

This post was originally published here. 

WASHINGTON — Eric Cantor has been here before.

In 2013, the House Republican, who had become the party’s de facto “chief political strategist,” was at a Virginia resort with his colleagues, working to shift the GOP away from its stereotype as a party focused on the rich and their corporate interests, according to a New Yorker profile of him at the time.

The party needed to prove, amid growing populist currents, that it wanted to improve the lives of everyday people — and Cantor, then the majority leader, was seen as the strategist to make it happen.

Continue to STAT+ to read the full story…

This post was originally published here. 

WASHINGTON — The upcoming midterm elections are setting the stage for unusually significant changes to key Senate committees that play an important role in health care.

Both the finance and health committees could undergo major changes, though for different reasons. Of course, if Democrats take control of the Senate, they would get to run the committees, though the GOP membership changes could still influence the panels’ directions.

At least five Republicans set to leave Senate Committee on Finance

The finance committee faces significant turnover as five or more of the panel’s 14 Republicans are set to leave: 

Continue to STAT+ to read the full story…

This post was originally published here. 

I am a transplant surgeon, and my patients are getting younger. Many are in their 30s and 40s — adults whose organ failure can be traced back to childhood obesity. And obesity itself can be a barrier to transplant, compounding the crisis it created.

The data confirm what I see clinically. Adolescents with severe obesity are up to nine times more likely to develop chronic kidney disease in young adulthood, even without diabetes or hypertension. Childhood fatty liver disease increases mortality risk 40-fold and has become the fastest-growing cause of liver transplants in young adults.

Read the rest…

This post was originally published here. 

Unpacking from vacation a couple months back, I decided to give artificial intelligence a task. I paused folding my laundry, sat down with Claude, and asked it to analyze the entirety of my genome.

Back in 2009, this was a task that quite literally took a village of 30 people — including me — working together to interpret the whole genome sequence of a colleague, friend, and fellow scientist named Stephen Quake. This endeavor brought together experts in genetics, computer science, pharmacology, and clinical medicine.

Read the rest…

This post was originally published here. 

Sanofi and Regeneron Pharmaceuticals, the duo behind the hugely successful drug Dupixent, are re-upping their partnership, with the companies announcing Thursday an expanded collaboration on a new series of antibodies for immunological diseases.

As part of the pact, Sanofi is paying Regeneron $1 billion upfront, with possible milestone payments of up to $7 billion more. The deal involves Regeneron taking the lead on research and development, with Sanofi spearheading commercial efforts. Profits on the medicines would be split evenly. 

“By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology,” George Yancopoulos, Regeneron’s chief scientific officer, said in a statement. 

Continue to STAT+ to read the full story…

This post was originally published here. 

WASHINGTON — The Trump administration published a final rule aimed at lowering Medicare prices for drugs administered in doctor offices. It applies to only four companies.

The Global Benchmark for Efficient Drug Pricing, or GLOBE, is one of two mandatory pilot programs that are part of President Trump’s plan to get drugmakers to lower prices in Medicare to levels charged in other rich countries, a policy generally referred to as most-favored nation pricing. The other pilot, called GUARD, is still in the proposed stage.

The pilots are tied to Trump’s separate voluntary deals with drugmakers to offer MFN prices to drugs for Medicaid recipients. The companies that struck those deals are exempt from the GLOBE pilot, according to the model’s final rule.

Continue to STAT+ to read the full story…

This post was originally published here. 

An investor lawsuit against UnitedHealth Group will move forward after a federal judge on Wednesday declined the company’s motion to dismiss allegations that it juiced its earnings to the tune of $3.3 billion in 2024 to conceal weakness in its Medicare Advantage business. 

It wasn’t all good news for the California Public Employees’ Retirement System, or CalPERS, though. U.S. District Judge Jeffrey Bryan dismissed most of the pension fund’s allegations that UnitedHealth’s leaders deceived investors about multiple aspects of their business in order to artificially inflate the company’s stock. Bryan agreed with UnitedHealth that most of the company statements CalPERS cited weren’t specific enough or represented typical promotional “puffery” that investors wouldn’t act on.

One of the lawsuit’s central allegations was that the Minnesota-based conglomerate concealed an illegal practice of making its Medicare Advantage patients appear sicker on paper to siphon more money from the government. On that front, CalPERS cited the company’s statements that home visits kept its members healthy and that its clinicians made independent clinical decisions. In fact, reporting has since shown that UnitedHealth used those visits to add diagnoses to patients’ records for which they received no follow-up care and pressured its doctors to do the same using bonuses.   .

Continue to STAT+ to read the full story…

This post was originally published here. 

WASHINGTON — The Department of Health and Human Services announced a set of new initiatives aimed at speeding up clinical trials by incorporating more artificial intelligence and computational models and moving away from sharply delineated trial phases. 

The centerpiece five-year program, dubbed SURPASS — “Simulation-augmented, Real-time Platform Adaptive Seamless Trials” — will kick off later this fall by accepting “ground-breaking ideas from cross-disciplinary teams in statistics, AI, and clinical trial design, operations, and regulation,” reads a website about the program. 

HHS is launching the program through the Advanced Research Projects Agency for Health. The initial announcement did not note how much funding was designated for the new initiatives, nor did it provide details on whether participants would be offered more flexibility or resources.  

Continue to STAT+ to read the full story…

This post was originally published here. 

The insurer said it’s trying to restrict hospitals from charging higher rates for services at off-campus outpatient departments. Hospital groups say the reimbursement cuts could threaten access to care.

This post was originally published here. 

Citing market uncertainty, the smart ring maker plans to delay a public offering that it had expected to raise up to $2.2 billion.

This post was originally published here. 

Many lawfully present immigrants will be among the first people to lose Medicaid coverage under congressional Republicans’ One Big Beautiful Bill Act, which is expected to cut spending by more than $900 billion through 2034 for the state-federal health program for people with low incomes or disabilities. The law will strip many more immigrants of their Affordable Care Act plan subsidies and Medicare coverage next year.

Read the rest…

This post was originally published here. 

This is the web edition of STAT’s AI Prognosis newsletter, our guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. 

It never crossed my mind that there would be a Cookie Monster AI satire piece in the New Yorker, but it does exist and I love it so much. h/t to my colleague Sarah Todd for sharing “Cookie Monster Tries to Meet His A.I. Mandate.”

News I missed, story tips, comments: aiprognosis@statnews.com

Continue to STAT+ to read the full story…

This post was originally published here.